Trial Profile
A postmarketing surveillance of natalizumab to evaluate the malignancy rates in multiple sclerosis patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Feb 2016
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- 24 Feb 2016 New trial record